NLS Pharmaceutics

General Information
Business:

We are an innovative biopharmaceutical company engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders, including narcolepsy and ADHD (Attention Deficit Hyperactivity Disorder). CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders.

(Note: This is a unit offering.)

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 4
Founded: 2015
Contact Information
Address Alter Postplatz 2, CH-6370 Stans, Switzerland
Phone Number +41.79.779.60.00
Web Address
View Prospectus: NLS Pharmaceutics
Financial Information
Market Cap $58.3mil
Revenues $0 mil (last 12 months)
Net Income $-6.5 mil (last 12 months)
IPO Profile
Symbol NLSP
Exchange NASDAQ
Shares (millions): 4.8
Price range $4.15 - $4.15
Est. $ Volume $20.0 mil
Manager / Joint Managers Maxim Group LLC
CO-Managers Brookline Capital (A division of Arcadia Securities)
Expected To Trade: 1/29/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change